Susquehanna International Group’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$245K Buy
56,010
+7,907
+16% +$37.3K ﹤0.01% 11306
2025
Q4
$243K Sell
48,103
-144,750
-75% -$672K ﹤0.01% 10441
2025
Q3
$669K Sell
192,853
-18,747
-9% -$70.4K ﹤0.01% 8307
2025
Q2
$719K Sell
211,600
-3,688
-2% -$12.3K ﹤0.01% 8294
2025
Q1
$863K Buy
215,288
+158,393
+278% +$821K ﹤0.01% 7622
2024
Q4
$369K Buy
56,895
+39,891
+235% +$238K ﹤0.01% 9367
2024
Q3
$94.2K Sell
17,004
-75,780
-82% -$430K ﹤0.01% 11089
2024
Q2
$518K Buy
92,784
+69,284
+295% +$416K ﹤0.01% 8177
2024
Q1
$158K Sell
23,500
-52,608
-69% -$416K ﹤0.01% 10859
2023
Q4
$694K Buy
+76,108
New +$479K ﹤0.01% 7858
2023
Q3
Sell
-67,320
Closed -$540K 12134
2023
Q2
$575K Sell
67,320
-239,700
-78% -$2.15M ﹤0.01% 7978
2023
Q1
$2.82M Buy
+307,020
New +$3.3M ﹤0.01% 4447
2022
Q4
Sell
-40,559
Closed -$545K 12594
2022
Q3
$597K Buy
+40,559
New +$527K ﹤0.01% 8005
2022
Q2
Sell
-23,590
Closed -$254K 13028
2022
Q1
$254K Buy
+23,590
New +$319K ﹤0.01% 10679

Other funds holding CTKB

Susquehanna International Group's CTKB Position: Q1 2026 in Review

Susquehanna International Group increased its Cytek Biosciences (CTKB) stake by 16% in Q1 2026, buying an estimated $37.3K and bringing the position to 56,010 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #11306.

Susquehanna International Group first reported a position in CTKB in Q1 2022 and has held it in 14 quarters since. The position peaked at $2.82M in Q1 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Susquehanna International Group held 56,010 shares of Cytek Biosciences worth $245K as of Q1 2026.
  • Susquehanna International Group bought 7,907 Cytek Biosciences shares in Q1 2026, an estimated $37.3K.
  • Cytek Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11306 holding.
  • Susquehanna International Group first reported a position in Cytek Biosciences in Q1 2022 and has held it in 14 quarters since.
  • Susquehanna International Group's Cytek Biosciences position peaked at $2.82M in Q1 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.